FDA Cancels Flu Vaccine Meeting, Raising Supply Concerns
Tap title to read story
The FDA's unexpected cancellation of its March flu vaccine advisory committee meeting raises concerns about sufficient vaccine supply for the 2025-2026 flu season. Drugmakers face tight deadlines and require the FDA's strain selection to begin production. While the WHO's recommendation may guide the FDA, it's unclear if this suffices for manufacturers to start production. The cancellation comes amid a severe flu season, sparking worries about potential vaccine shortages and impacting lives. The FDA says it will announce its recommendations in time for the upcoming flu season, but the reason for cancellation remains unexplained.
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.